أمل جديد لمرضى السكري.. علاج بحقنة أسبوعية

Researchers revealed during the American Diabetes Association events a promising medical advancement for treating type 2 diabetes, represented by the launch of a weekly injection as an alternative to daily insulin injections. Clinical studies have shown that efsitora alfa insulin produced by Eli Lilly - also known as LY3209590 - has similar efficacy to traditional daily injections like insulin de, with greater convenience for the patient.

The phase three trials included about 1,000 adults with type 2 diabetes, and their results indicated that the weekly injections demonstrated significant control over HbA1c levels, the gold standard for blood sugar regulation, without a significant increase in the risk of hypoglycemia compared to traditional methods. With these innovations, it is expected that patient adherence to treatment will improve in the long term, given the ease of using injections compared to the daily routine.

This step is the result of ongoing efforts to avoid the complications of daily insulin injections and improve the quality of life for diabetes patients, while scientists continue to develop long-acting medications similar to insulin icodec ("Awiqli") with a once-a-week dosage, which was approved in Canada and the European Union in 2024.